New vaccine aims to broaden protection against pneumonia
NCT ID NCT07105722
Summary
This early-stage study is testing a new pneumonia vaccine called Pn-MAPS30plus in 127 healthy adults aged 50-64. The vaccine aims to protect against more strains of pneumonia bacteria than current vaccines. Researchers will check if the vaccine is safe and if it triggers a good immune response in participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMONIA, BACTERIAL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Norwood, South Australia, 5067, Australia
-
GSK Investigational Site
Bayswater, Victoria, 3153, Australia
-
GSK Investigational Site
Camberwell, Victoria, 3124, Australia
-
GSK Investigational Site
East Melbourne, Victoria, 3002, Australia
Conditions
Explore the condition pages connected to this study.